An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, Phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents - Commentary

Tom Huizinga; Peter Nigrovic; Eric Ruderman; Hendrik Schulze-Koops

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, Phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents - Commentary

Tom Huizinga^*, Peter Nigrovic, Eric Ruderman, Hendrik Schulze-Koops

^*Corresponding author for this work

Medicine, Rheumatology Division

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	74
Number of pages	1
Journal	International Journal of Advances in Rheumatology
Volume	9
Issue number	2
State	Published - 2011

ASJC Scopus subject areas

Rheumatology

Cite this

Huizinga, Tom ; Nigrovic, Peter ; Ruderman, Eric et al. / An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis : A three-month randomized, placebo-controlled, Phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents - Commentary. In: International Journal of Advances in Rheumatology. 2011 ; Vol. 9, No. 2. pp. 74.

@article{b64531c170b547568f60b0594519e172,

title = "An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, Phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents - Commentary",

author = "Tom Huizinga and Peter Nigrovic and Eric Ruderman and Hendrik Schulze-Koops",

year = "2011",

language = "English (US)",

volume = "9",

pages = "74",

journal = "International Journal of Advances in Rheumatology",

issn = "1478-856X",

publisher = "Remedica Medical Education and Publishing Ltd",

number = "2",

}

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, Phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents - Commentary. / Huizinga, Tom; Nigrovic, Peter; Ruderman, Eric et al.
In: International Journal of Advances in Rheumatology, Vol. 9, No. 2, 2011, p. 74.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis

T2 - A three-month randomized, placebo-controlled, Phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents - Commentary

AU - Huizinga, Tom

AU - Nigrovic, Peter

AU - Ruderman, Eric

AU - Schulze-Koops, Hendrik

PY - 2011

Y1 - 2011

UR - http://www.scopus.com/inward/record.url?scp=84863822075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863822075&partnerID=8YFLogxK

M3 - Comment/debate

AN - SCOPUS:84863822075

SN - 1478-856X

VL - 9

SP - 74

JO - International Journal of Advances in Rheumatology

JF - International Journal of Advances in Rheumatology

IS - 2

ER -

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, Phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents - Commentary

ASJC Scopus subject areas

Other files and links

Cite this